Frequency of TERT promoter mutations in human cancers
- PMID: 23887589
- DOI: 10.1038/ncomms3185
Frequency of TERT promoter mutations in human cancers
Abstract
Reactivation of telomerase has been implicated in human tumorigenesis, but the underlying mechanisms remain poorly understood. Here we report the presence of recurrent somatic mutations in the TERT promoter in cancers of the central nervous system (43%), bladder (59%), thyroid (follicular cell-derived, 10%) and skin (melanoma, 29%). In thyroid cancers, the presence of TERT promoter mutations (when occurring together with BRAF mutations) is significantly associated with higher TERT mRNA expression, and in glioblastoma we find a trend for increased telomerase expression in cases harbouring TERT promoter mutations. Both in thyroid cancers and glioblastoma, TERT promoter mutations are significantly associated with older age of the patients. Our results show that TERT promoter mutations are relatively frequent in specific types of human cancers, where they lead to enhanced expression of telomerase.
Similar articles
-
Upregulating mutations in the TERT promoter commonly occur in adult malignant gliomas and are strongly associated with total 1p19q loss.Acta Neuropathol. 2013 Aug;126(2):267-76. doi: 10.1007/s00401-013-1141-6. Epub 2013 Jun 14. Acta Neuropathol. 2013. PMID: 23764841
-
TERT promoter mutation as an early genetic event activating telomerase in follicular thyroid adenoma (FTA) and atypical FTA.Cancer. 2014 Oct 1;120(19):2965-79. doi: 10.1002/cncr.28800. Epub 2014 Jun 4. Cancer. 2014. PMID: 24898513
-
TERT promoter mutations in cancer development.Curr Opin Genet Dev. 2014 Feb;24:30-7. doi: 10.1016/j.gde.2013.11.005. Epub 2013 Dec 20. Curr Opin Genet Dev. 2014. PMID: 24657534 Review.
-
Telomerase in differentiated thyroid cancer: promoter mutations, expression and localization.Mol Cell Endocrinol. 2015 Jan 5;399:288-95. doi: 10.1016/j.mce.2014.10.019. Epub 2014 Oct 27. Mol Cell Endocrinol. 2015. PMID: 25448848
-
TERT gene: its function and dysregulation in cancer.J Clin Pathol. 2019 Apr;72(4):281-284. doi: 10.1136/jclinpath-2018-205653. Epub 2019 Jan 29. J Clin Pathol. 2019. PMID: 30696697 Review.
Cited by
-
TERT Promoter Mutation Analysis for Blood-Based Diagnosis and Monitoring of Gliomas.Clin Cancer Res. 2021 Jan 1;27(1):169-178. doi: 10.1158/1078-0432.CCR-20-3083. Epub 2020 Oct 13. Clin Cancer Res. 2021. PMID: 33051308 Free PMC article.
-
Telomere and Telomerase Therapeutics in Cancer.Genes (Basel). 2016 May 26;7(6):22. doi: 10.3390/genes7060022. Genes (Basel). 2016. PMID: 27240403 Free PMC article. Review.
-
Molecular pathogenesis of pediatric thyroid carcinoma.J Radiat Res. 2021 May 5;62(Supplement_1):i71-i77. doi: 10.1093/jrr/rraa096. J Radiat Res. 2021. PMID: 33978172 Free PMC article. Review.
-
Telomerase and CD4 T Cell Immunity in Cancer.Cancers (Basel). 2020 Jun 25;12(6):1687. doi: 10.3390/cancers12061687. Cancers (Basel). 2020. PMID: 32630460 Free PMC article. Review.
-
Tumor-Agnostic Circulating Tumor DNA Testing for Monitoring Muscle-Invasive Bladder Cancer.Int J Mol Sci. 2023 Nov 21;24(23):16578. doi: 10.3390/ijms242316578. Int J Mol Sci. 2023. PMID: 38068899 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials